NCT00277225

A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris

A Phase I,Randomized, Double Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (planned)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this protocol is to determine the single-dose pharmacokinetics and immunogicity of BMS-188667 administered as a 1 hour intravenous infusion with extended pharmacokinetic sampling. Safety of all subjects will be assessed in a double blind fashion through the inclusion of placebo controls at each dose level.

Conditions

• Psoriasis Vulgaris

Interventions

Type	Name	Description
DRUG	Abatacept

Timeline

• Start date: 1995-11-01
• Primary completion: 1996-06-01
• Completion: 1996-06-01
• First posted: 2006-01-16
• Last updated: 2011-04-13

Locations

1 site across 1 country: United States